Free Trial
NASDAQ:CRMD

CorMedix (CRMD) Stock Price, News & Analysis

CorMedix logo
$14.35 +0.00 (+0.01%)
As of 09:46 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About CorMedix Stock (NASDAQ:CRMD)

Key Stats

Today's Range
$14.33
$14.33
50-Day Range
$10.07
$16.56
52-Week Range
$5.31
$17.43
Volume
1,595 shs
Average Volume
1.96 million shs
Market Capitalization
$1.07 billion
P/E Ratio
19.19
Dividend Yield
N/A
Price Target
$17.33
Consensus Rating
Moderate Buy

Company Overview

CorMedix Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
56th Percentile Overall Score

CRMD MarketRank™: 

CorMedix scored higher than 56% of companies evaluated by MarketBeat, and ranked 502nd out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    CorMedix has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 4 buy ratings, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    CorMedix has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about CorMedix's stock forecast and price target.
  • Earnings Growth

    Earnings for CorMedix are expected to grow in the coming year, from ($0.32) to $0.94 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of CorMedix is 19.13, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 28.75.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of CorMedix is 19.13, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 31.26.

  • Price to Book Value per Share Ratio

    CorMedix has a P/B Ratio of 4.85. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about CorMedix's valuation and earnings.
  • Percentage of Shares Shorted

    15.11% of the float of CorMedix has been sold short.
  • Short Interest Ratio / Days to Cover

    CorMedix has a short interest ratio ("days to cover") of 4.6.
  • Change versus previous month

    Short interest in CorMedix has recently increased by 6.27%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    CorMedix does not currently pay a dividend.

  • Dividend Growth

    CorMedix does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    15.11% of the float of CorMedix has been sold short.
  • Short Interest Ratio / Days to Cover

    CorMedix has a short interest ratio ("days to cover") of 4.6.
  • Change versus previous month

    Short interest in CorMedix has recently increased by 6.27%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    CorMedix has a news sentiment score of 1.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.03 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 6 news articles for CorMedix this week, compared to 5 articles on an average week.
  • Search Interest

    18 people have searched for CRMD on MarketBeat in the last 30 days. This is an increase of 64% compared to the previous 30 days.
  • MarketBeat Follows

    6 people have added CorMedix to their MarketBeat watchlist in the last 30 days. This is an increase of 20% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, CorMedix insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 5.30% of the stock of CorMedix is held by insiders.

  • Percentage Held by Institutions

    Only 34.18% of the stock of CorMedix is held by institutions.

  • Read more about CorMedix's insider trading history.
Receive CRMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CorMedix and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CRMD Stock News Headlines

Elon’s BIGGEST warning yet?
Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.tc pixel
CorMedix to Participate in Upcoming Investor Conferences
CorMedix: The Undervalued Breakthrough
See More Headlines

CRMD Stock Analysis - Frequently Asked Questions

CorMedix's stock was trading at $8.10 at the start of the year. Since then, CRMD stock has increased by 77.2% and is now trading at $14.35.

CorMedix Inc (NASDAQ:CRMD) released its quarterly earnings results on Thursday, August, 7th. The company reported $0.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.20 by $0.08. The firm's revenue for the quarter was up 4830.1% compared to the same quarter last year.

CorMedix's stock reverse split before market open on Tuesday, March 26th 2019.The 1-5 reverse split was announced on Thursday, March 21st 2019. The number of shares owned by shareholders was adjusted after the closing bell on Monday, March 25th 2019. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.

Top institutional investors of CorMedix include Marshall Wace LLP (3.46%), Geode Capital Management LLC (2.35%), Palisades Investment Partners LLC (0.83%) and Kennedy Capital Management LLC (0.64%). Insiders that own company stock include Joseph Todisco, Erin Mistry and Elizabeth Hurlburt.
View institutional ownership trends
.

Shares of CRMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that CorMedix investors own include Voyager Therapeutics (VYGR), Waste Connections (WCN), American Water Works (AWK), DiamondRock Hospitality (DRH), AU Optronics (AUOTY), Marinus Pharmaceuticals (MRNS) and The RMR Group (RMR).

Company Calendar

Last Earnings
8/07/2025
Today
8/29/2025
Next Earnings (Estimated)
10/29/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CRMD
CIK
1410098
Employees
30
Year Founded
N/A

Price Target and Rating

High Price Target
$20.00
Low Price Target
$15.00
Potential Upside/Downside
+20.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.86
Research Coverage
7 Analysts

Profitability

EPS (Trailing Twelve Months)
$0.75
Trailing P/E Ratio
19.13
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$17.93 million
Net Margins
42.11%
Pretax Margin
42.54%
Return on Equity
42.73%
Return on Assets
34.19%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
7.82
Quick Ratio
7.52

Sales & Book Value

Annual Sales
$43.47 million
Price / Sales
24.64
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.96 per share
Price / Book
4.85

Miscellaneous

Outstanding Shares
74,650,000
Free Float
70,693,000
Market Cap
$1.07 billion
Optionable
Optionable
Beta
1.71

Social Links

Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

This page (NASDAQ:CRMD) was last updated on 8/29/2025 by MarketBeat.com Staff
From Our Partners